Thereby, the interplay between PIM kinases and NFATC1 may also provide possibilities for therapeutic interventions against metastatic prostate cancer through combinatory approaches involving PIM-selective kinase inhibitors. The gene discussed is NFATC1; the disease is metastatic prostate carcinoma.